Long Ideas - As expected, the FDA will require Ventrus Biosciences (NASDAQ:VTUS) to complete a second Phase III study of diltiazem hydrochloride cream (VEN-307) before submitting a New … Continue Reading
Read NowLong Ideas - When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology … Continue Reading
Read NowLong Ideas - Shares of Endo Pharmaceuticals (NASDAQ:ENDP) are trading at a deep discount to other pharmaceutical companies, with the last dip in price coming on the heels … Continue Reading
Read NowLong Ideas - Onyx Pharmaceuticals (NASDAQ:ONXX) got the better of earnings estimates for the 3rd quarter of 2012, with non-GAAP net loss per share of $.79 compared to … Continue Reading
Read NowLong Ideas - Oncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investments totaled $140M on Sept. 30, and … Continue Reading
Read NowLong Ideas - Merge Healthcare (NASDAQ:MRGE) reported adjusted 3Q 2012 revenues and EPS of $61.0 million and $0.01, compared to Wall St. Consensus expectations of $62.9 million and … Continue Reading
Read NowLong Ideas - One of the most pressing issues that the market faces today is what kind of impact the fiscal cliff will have on companies in the … Continue Reading
Read Now